Table 2.

Baseline clinicopathological characteristics according to CAR.

Characteristics	CAR < 0.156 n = 82	CAR ≥ 0.156 n = 60	P-value
Gender
Male	49 (53.3%)	43 (46.7%)	0.142
Female	33 (66.0%)	17 (34.0%)
Age
<60	39 (63.9%)	22 (36.1%)	0.195
≥60	43 (53.1%)	38 (46.9%)
ECOG PS
2	9 (45.0%)	11 (55.0%)	0.213
0–1	73 (59.8%)	49 (40.2%)
Primary tumor location
Head and neck	35 (57.4%)	26 (42.6%)	0.938
Body and tail	47 (58.0%)	34 (42.0%)
TNM stage
III	33 (80.5%)	8 (19.5%)	<0.001
IV	49 (48.5%)	52 (51.5%)
Liver metastasis
Yes	35 (49.3%)	36 (50.7%)	0.041
No	47 (66.2%)	24 (33.8%)
Chemotherapy
Gemcitabine monotherapy	31 (62.0%)	19 (38.0%)	0.449
Others	51 (55.4%)	41 (44.6%)
AST (IU/L)
<40	60 (63.8%)	34 (36.2%)	0.040
≥40	22 (45.8%)	26 (54.2%)
ALT (IU/L)
<40	63(59.4%)	43 (40.6%)	0.485
≥40	19 (52.8%)	17 (47.2%)
CA19-9 (U/ml)
<1000	51 (60.0%)	34 (40.0%)	0.507
≥1000	31 (54.4%)	26 (45.6%)
CEA (ng/ml)
<5	36 (64.3%)	20 (35.7%)	0.203
≥5	46 (53.5%)	40 (46.5%)
Hemoglobin (g/L)
<120	33 (51.6%)	31 (48.4%)	0.177
≥120	49 (62.8%)	60 (42.3%)